Alpha Gliadin IgG

If you have suspected a gluten problem but never gotten a clear answer, this is one of the older blood tests aimed at that question. It looks for an immune reaction to a wheat protein, and a raised level can be an early hint that your body treats gluten as a threat.

The catch is that this marker is neither the most accurate nor the most specific way to check for gluten-related disease. It is best read as a clue, not a verdict, and a positive result should send you toward sharper follow-up testing rather than a diagnosis.

What This Antibody Actually Measures

The test measures gliadin IgG (immunoglobulin G, a class of antibody, directed against gliadin, one of the wheat proteins inside gluten). In research settings the gliadin family is broken into fractions such as alpha-gliadin, but most clinical laboratories measure the broader anti-gliadin antibody response. Your body makes it through immune cells called B cells that produce antibodies when they repeatedly encounter gluten in the gut.

So the number reflects an immune response to eating gluten, not a direct measurement of tissue damage. Gliadin antibodies can even appear before the more specific antibodies that define celiac disease, which is part of why they were once used as an early screen.

What a High Level Signals

The strongest association is with untreated celiac disease, where levels are meaningfully higher than in healthy people. When someone with celiac disease removes gluten, the level tends to fall, which is why a high value usually points to active gluten-driven immune activity rather than a permanent trait.

A raised result is not proof of any single condition. This antibody can be elevated in people without celiac disease, so a high number tells you your immune system is engaging gluten, not why.

Celiac Disease

Historically, this antibody helped screen for celiac disease, especially before more specific tests existed. In one outpatient study, it caught about 82 out of 100 people who had celiac disease and correctly cleared about 87 out of 100 who did not, and in a group of 90 patients it was raised in 36 of 44 with biopsy-confirmed celiac disease and in only 6 of 46 with a normal gut lining.

That performance is still limited by today's standards. A later study found the conventional (native) gliadin IgG test flagged only about 42 out of 100 confirmed celiac cases, while correctly clearing about 90 out of 100 people without it. Current guidelines instead build celiac diagnosis around a tissue transglutaminase IgA antibody (tTG-IgA) test plus a total IgA measurement, not gliadin IgG. A major review goes further, concluding that the first-generation native gliadin antibody test should no longer be used to evaluate for celiac disease.

Where Else This Antibody Shows Up

The reason a positive result cannot stand alone is that gliadin antibodies appear in many other settings. In one study of sarcoidosis (an inflammatory disease affecting multiple organs), raised gliadin IgG was found in 41 of 99 patients. Elevated gliadin antibodies also occur in roughly 10 percent of the general population, produced as a response to gluten without necessarily signaling disease.

The marker has been studied in psychiatric conditions too. In schizophrenia cohorts, elevated gliadin IgG was reported in about 30 percent of patients versus about 20 percent of comparison subjects, and across studies people with schizophrenia have been roughly two to six times as likely to test positive. Those findings are cross-sectional and exploratory, meaning they describe an association at one point in time, not a cause or a diagnosis.

This is not a simple good-number or bad-number marker. It is an indicator of gluten-directed immune activity, and different people can carry these antibodies for very different reasons. A raised value tells you your immune system is reacting to gluten; it does not tell you which condition, if any, is responsible, which is exactly why it needs pairing with more specific tests.

Tracking Changes Over Time

A single reading is less useful than watching the direction of travel. In people with celiac disease, gliadin antibody levels fall on a gluten-free diet, and that decline tends to parallel healing of the gut lining. In one study, levels dropped in seven of eight patients whose intestinal lining improved on the diet, while remaining raised in those who kept eating gluten and did not improve.

If you want trend data, get a baseline while you are still eating gluten, retest in 3 to 6 months if you change your diet, then at least once a year. This monitoring rhythm is borrowed from how celiac blood tests are tracked in general, since guidelines recommend following tTG-IgA every 6 to 12 months after starting a gluten-free diet rather than gliadin IgG specifically. One important limit applies: the evidence that levels fall comes largely from people with celiac disease, so falling numbers are most meaningful in that context rather than as a general wellness signal.

When a Single Reading Can Mislead

• Already off gluten: if you have cut gluten before testing, this level can read low or normal even if your body would react, because the immune stimulation has been removed. For a valid result you generally need to be eating gluten regularly beforehand.
• Low or absent total IgA: an isolated positive gliadin IgG can be a false alarm. In one study, all 22 patients positive for gliadin antibody alone had a normal intestinal lining.
• Other conditions: because gliadin antibodies appear in sarcoidosis, some psychiatric cohorts, and a slice of healthy people, a positive result on its own does not confirm a gut disease.

What to Do With an Unexpected Result

If this comes back high, do not treat it as a celiac diagnosis and do not start a gluten-free diet on the strength of it alone. The most useful next step is to order a tTG-IgA test together with a total IgA measurement, since that pairing is the guideline-preferred first line and the total IgA tells you whether an IgA-based result can be trusted.

Keep eating gluten until you are fully worked up, because going gluten-free first can erase the very signals a workup depends on. If tTG-IgA is positive, a gastroenterologist can advise on confirmatory endomysial antibody (EMA-IgA) testing or a duodenal biopsy, which remains the reference standard. If standard serology is negative but symptoms persist, checking total IgA for a deficiency and considering a deamidated gliadin peptide IgG (DGP-IgG) test, which guidelines highlight especially when IgA is low, are reasonable moves to discuss with a clinician.